Potassium channels as drugs targets in therapy of cardiovascular diseases: 25 years later

Potassium channels are the most variable ion channel group. They participate in numerous cardiovascular functions, for example regulation of vascular tone, maintenance of resting cardiac membrane potential and excitability of cardiac conduction tissue. Both drugs and endogenous ligands could modulat...

Full description

Bibliographic Details
Main Authors: Protić Dragana, Todorović Zoran, Gojković-Bukarica Ljiljana
Format: Article
Language:English
Published: Association of medical doctors Sanamed Novi Pazar 2013-03-01
Series:Sanamed
Subjects:
Online Access:http://sanamed.rs/sanamed_pdf/sanamed_8_1/KALIJUMOVI_KANALI%20.pdf
_version_ 1797281577584033792
author Protić Dragana
Todorović Zoran
Gojković-Bukarica Ljiljana
author_facet Protić Dragana
Todorović Zoran
Gojković-Bukarica Ljiljana
author_sort Protić Dragana
collection DOAJ
description Potassium channels are the most variable ion channel group. They participate in numerous cardiovascular functions, for example regulation of vascular tone, maintenance of resting cardiac membrane potential and excitability of cardiac conduction tissue. Both drugs and endogenous ligands could modulate potassium channel function, belonging to the potassium channel blockers or openers. Modulation of potassium channels could be a therapeutic or adverse drug action. Class III antiarrhythmic agents block the potassium channels, thereby prolonging repolarization phase of action potential with resulting prolongation of effective refractory period. Their effectiveness against supraventricular and ventricular arrhythmias should be weighted against their proarrhythmogenic potential. In addition, numerous other antiarrhythmic agents could modulate potassium channels as well. Diazoxide, minoxidil and nicorandil (well known arterial vasodilators), as well as numerous newly synthesized substances with still unknown therapeutic potential, belong to the potassium channel activators/openers. Therapeutic use of such vasodilators may involve treatment of hypertension (diazoxide, minoxidil) and stable angina (nicorandil). Their use might be accompanied with side effects, such as vasodilation, edema, hypotension and reflex tachycardia. Potassium channel openers have also an important role in the treatment of peripheral vascular disease and pulmonary hypertension. In the future, drugs with selective effects on the vascular or cardiac potassium channels could be useful therapeutic agents.
first_indexed 2024-03-07T16:59:25Z
format Article
id doaj.art-da4e25b1995042c3a8ff492da2a65d60
institution Directory Open Access Journal
issn 1452-662X
2217-8171
language English
last_indexed 2024-03-07T16:59:25Z
publishDate 2013-03-01
publisher Association of medical doctors Sanamed Novi Pazar
record_format Article
series Sanamed
spelling doaj.art-da4e25b1995042c3a8ff492da2a65d602024-03-03T03:26:32ZengAssociation of medical doctors Sanamed Novi PazarSanamed1452-662X2217-81712013-03-01817178Potassium channels as drugs targets in therapy of cardiovascular diseases: 25 years laterProtić Dragana0Todorović Zoran1Gojković-Bukarica Ljiljana2Department of Pharmacology, Clinical Pharmacology and Toxicology, Faculty of Medicine, University of Belgrade, Belgrade, SerbiaDepartment of Pharmacology, Clinical Pharmacology and Toxicology, Faculty of Medicine, University of Belgrade, Belgrade, SerbiaDepartment of Pharmacology, Clinical Pharmacology and Toxicology, Faculty of Medicine, University of Belgrade, Belgrade, SerbiaPotassium channels are the most variable ion channel group. They participate in numerous cardiovascular functions, for example regulation of vascular tone, maintenance of resting cardiac membrane potential and excitability of cardiac conduction tissue. Both drugs and endogenous ligands could modulate potassium channel function, belonging to the potassium channel blockers or openers. Modulation of potassium channels could be a therapeutic or adverse drug action. Class III antiarrhythmic agents block the potassium channels, thereby prolonging repolarization phase of action potential with resulting prolongation of effective refractory period. Their effectiveness against supraventricular and ventricular arrhythmias should be weighted against their proarrhythmogenic potential. In addition, numerous other antiarrhythmic agents could modulate potassium channels as well. Diazoxide, minoxidil and nicorandil (well known arterial vasodilators), as well as numerous newly synthesized substances with still unknown therapeutic potential, belong to the potassium channel activators/openers. Therapeutic use of such vasodilators may involve treatment of hypertension (diazoxide, minoxidil) and stable angina (nicorandil). Their use might be accompanied with side effects, such as vasodilation, edema, hypotension and reflex tachycardia. Potassium channel openers have also an important role in the treatment of peripheral vascular disease and pulmonary hypertension. In the future, drugs with selective effects on the vascular or cardiac potassium channels could be useful therapeutic agents.http://sanamed.rs/sanamed_pdf/sanamed_8_1/KALIJUMOVI_KANALI%20.pdfkalijumovi kanaliblokatori kalijumovih kanalaantiaritmiciotvarači kalijumovih kanalakardiovaskularni sistem
spellingShingle Protić Dragana
Todorović Zoran
Gojković-Bukarica Ljiljana
Potassium channels as drugs targets in therapy of cardiovascular diseases: 25 years later
Sanamed
kalijumovi kanali
blokatori kalijumovih kanala
antiaritmici
otvarači kalijumovih kanala
kardiovaskularni sistem
title Potassium channels as drugs targets in therapy of cardiovascular diseases: 25 years later
title_full Potassium channels as drugs targets in therapy of cardiovascular diseases: 25 years later
title_fullStr Potassium channels as drugs targets in therapy of cardiovascular diseases: 25 years later
title_full_unstemmed Potassium channels as drugs targets in therapy of cardiovascular diseases: 25 years later
title_short Potassium channels as drugs targets in therapy of cardiovascular diseases: 25 years later
title_sort potassium channels as drugs targets in therapy of cardiovascular diseases 25 years later
topic kalijumovi kanali
blokatori kalijumovih kanala
antiaritmici
otvarači kalijumovih kanala
kardiovaskularni sistem
url http://sanamed.rs/sanamed_pdf/sanamed_8_1/KALIJUMOVI_KANALI%20.pdf
work_keys_str_mv AT proticdragana potassiumchannelsasdrugstargetsintherapyofcardiovasculardiseases25yearslater
AT todoroviczoran potassiumchannelsasdrugstargetsintherapyofcardiovasculardiseases25yearslater
AT gojkovicbukaricaljiljana potassiumchannelsasdrugstargetsintherapyofcardiovasculardiseases25yearslater